Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ZKF001
MIFTS: 51

Zika Fever

Categories: Infectious diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Zika Fever

About this section

MalaCards integrated aliases for Zika Fever:

Name: Zika Fever 12 20 15
Zika Virus Infection 20 58 3 44 70
Zika Virus Disease 12 20 58
Zika Virus 73 42

Characteristics:

Orphanet epidemiological data:

58
zika virus disease
Inheritance: Not applicable; Prevalence: 1-5/10000 (Brazil); Age of onset: All ages; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 32
Orphanet: 58  
Rare infectious diseases


Sources

Summaries for Zika Fever

About this section
MedlinePlus : 42 Zika is a virus that is spread mostly by mosquitoes. A pregnant mother can pass it to her baby during pregnancy or around the time of birth. It can spread through sexual contact. There have also been reports that the virus has spread through blood transfusions. There have been outbreaks of Zika virus in the United States, Africa, Southeast Asia, the Pacific Islands, parts of the Caribbean, and Central and South America. Most people who get the virus do not get sick. One in five people do get symptoms, which can include a fever, rash, joint pain, and conjunctivitis (pink eye). Symptoms are usually mild, and start 2 to 7 days after being bitten by an infected mosquito. A blood test can tell whether you have the infection. There are no vaccines or medicines to treat it. Drinking lots of fluids, resting, and taking acetaminophen might help. Zika can cause microcephaly (a serious birth defect of the brain) and other problems in babies whose mothers were infected while pregnant. The Centers for Disease Control and Prevention recommends that pregnant women do not travel to areas where there is a Zika virus outbreak. If you do decide to travel, first talk to your doctor. You should also be careful to prevent mosquito bites: Use insect repellent Wear clothes that cover your arms, legs, and feet Stay in places that have air conditioning or that use window and door screens Centers for Disease Control and Prevention

MalaCards based summary : Zika Fever, also known as zika virus infection, is related to encephalitis and west nile fever, and has symptoms including fever, rash and headaches. An important gene associated with Zika Fever is AXL (AXL Receptor Tyrosine Kinase), and among its related pathways/superpathways are Herpes simplex virus 1 infection and Measles. The drugs Immunologic Factors and Aluminum hydroxide have been mentioned in the context of this disorder. Affiliated tissues include eye, placenta and fetal brain, and related phenotypes are maculopapular exanthema and arthritis

Disease Ontology : 12 A viral infectious disease that has material basis in Zika virus, which is transmitted by Aedes aegypti mosquitoes and targets neural progenitor cells and neuronal cells in all stages of maturity and has symptom fever, has symptom rash, has symptom headaches and has symptom joint pain.

GARD : 20 Zika virus infection is spread to people primarily through the bite of an infected mosquito. Zika virus can also be spread from a pregnant mother to her child and through sexual contact with an affected partner. Cases of Zika virus transmission via blood transfusion have also been reported. Zika virus outbreaks are currently occurring in many countries. The illness associated with Zika virus infection is usually mild, with symptoms lasting for several days to a week. The most common symptoms of Zika are fever, rash, joint pain, and conjunctivitis (red eyes). However, research has suggested an association between Zika virus infection and Guillain-Barre syndrome (GBS) in a small percentage of cases. Zika virus infection during pregnancy can cause adverse pregnancy outcomes, including microcephaly and other serious brain defects. The full range of health problems associated with Zika virus infection during pregnancy is currently being studied. No vaccine currently exists to prevent Zika virus infection, but there are still ways to protect oneself. The CDC recommends that pregnant women consider postponing travel to Zika-affected areas. People living in or traveling to areas where Zika virus is found should take steps to prevent mosquito bites. Those who have traveled to Zika-affected areas may wish to take steps to prevent sexual transmission of the Zika virus.

CDC : 3 Zika is spread mostly by the bite of an infected Aedes species mosquito (Ae. aegypti and Ae. albopictus). These mosquitoes bite during the day and night. Zika can be passed from a pregnant woman to her fetus. Infection during pregnancy can cause certain birth defects. There is no vaccine or medicine for Zika.

Wikipedia : 73 Zika virus (ZIKV) (pronounced /ˈziːkə/ or /ˈzɪkə/) is a member of the virus family Flaviviridae. It is... more...

Sources

Related Diseases for Zika Fever

About this section

Diseases related to Zika Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 368)
# Related Disease Score Top Affiliating Genes
1 encephalitis 30.4 TLR3 ERVW-1 DDX58 CD209
2 west nile fever 30.3 ERVW-1 CD209
3 dengue shock syndrome 30.1 STAT2 ERVW-1 CD209
4 tick-borne encephalitis 30.1 TLR3 DDX58 CD209
5 ebola hemorrhagic fever 29.9 ERVW-1 DDX58
6 herpes simplex 29.8 TLR3 STAT2 DDX58 CD209
7 dengue hemorrhagic fever 29.8 TLR3 STAT2 IFNAR1 CD209
8 dengue virus 29.6 STAT2 DDX58 CD209
9 lymphocytic choriomeningitis 29.6 TYRO3 DDX58 CD209 AXL
10 measles 29.5 TLR3 STAT2 IFNAR1 DDX58 CD209
11 poliomyelitis 29.3 TLR3 DDX58
12 mouth disease 29.3 TLR3 DDX58 CD209
13 japanese encephalitis 29.0 TLR3 STAT2 DDX58 CD209
14 viral infectious disease 28.9 TLR3 STAT2 IFNAR1 ERVW-1 DDX58 CD209
15 zika virus congenital syndrome 11.6
16 torch syndrome 11.1
17 congenital amyoplasia 10.5
18 glioblastoma 10.5
19 toxoplasmosis 10.5
20 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.5
21 syphilis 10.5
22 hydrocephalus 10.4
23 neuroblastoma 10.4
24 agenesis of corpus callosum, cardiac, ocular, and genital syndrome 10.4
25 stomatitis 10.4
26 cytokine deficiency 10.4
27 malaria 10.4
28 lissencephaly 10.4
29 dysphagia 10.4
30 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.3
31 cerebellar hypoplasia 10.3
32 infertility 10.3
33 thrombocytopenia 10.3
34 neural tube defects 10.3
35 sensorineural hearing loss 10.3
36 acute disseminated encephalomyelitis 10.3
37 transverse myelitis 10.3
38 severe acute respiratory syndrome 10.3
39 primary microcephaly 10.3
40 demyelinating polyneuropathy 10.3
41 placenta disease 10.3
42 meningoencephalitis 10.2
43 polymicrogyria with or without vascular-type ehlers-danlos syndrome 10.2
44 cortical dysplasia, complex, with other brain malformations 10 10.2
45 middle east respiratory syndrome 10.2
46 male infertility 10.2
47 cerebral palsy 10.2
48 purpura 10.2
49 polymicrogyria 10.2
50 arbovirosis 10.2

Graphical network of the top 20 diseases related to Zika Fever:



Diseases related to Zika Fever
Sources

Symptoms & Phenotypes for Zika Fever

About this section

Human phenotypes related to Zika Fever:

58 31 (show all 34)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 maculopapular exanthema 58 31 hallmark (90%) Very frequent (99-80%) HP:0040186
2 arthritis 58 31 frequent (33%) Frequent (79-30%) HP:0001369
3 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
4 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
5 myalgia 58 31 frequent (33%) Frequent (79-30%) HP:0003326
6 conjunctivitis 58 31 frequent (33%) Frequent (79-30%) HP:0000509
7 headache 58 31 frequent (33%) Frequent (79-30%) HP:0002315
8 pruritus 58 31 frequent (33%) Frequent (79-30%) HP:0000989
9 increased circulating igm level 58 31 frequent (33%) Frequent (79-30%) HP:0003496
10 abnormality of the cerebrospinal fluid 58 31 frequent (33%) Frequent (79-30%) HP:0002921
11 vomiting 58 31 occasional (7.5%) Occasional (29-5%) HP:0002013
12 edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0000969
13 wrist swelling 58 31 occasional (7.5%) Occasional (29-5%) HP:0001225
14 ankle swelling 58 31 occasional (7.5%) Occasional (29-5%) HP:0001785
15 transient hearing impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0012779
16 encephalitis 58 31 very rare (1%) Very rare (<4-1%) HP:0002383
17 microcephaly 58 31 very rare (1%) Very rare (<4-1%) HP:0000252
18 intrauterine growth retardation 58 31 very rare (1%) Very rare (<4-1%) HP:0001511
19 thrombocytopenia 58 31 very rare (1%) Very rare (<4-1%) HP:0001873
20 lens subluxation 58 31 very rare (1%) Very rare (<4-1%) HP:0001132
21 iris coloboma 58 31 very rare (1%) Very rare (<4-1%) HP:0000612
22 meningitis 58 31 very rare (1%) Very rare (<4-1%) HP:0001287
23 subcutaneous hemorrhage 58 31 very rare (1%) Very rare (<4-1%) HP:0001933
24 spontaneous abortion 58 31 very rare (1%) Very rare (<4-1%) HP:0005268
25 optic disc hypoplasia 58 31 very rare (1%) Very rare (<4-1%) HP:0007766
26 abnormality of the optic disc 58 31 very rare (1%) Very rare (<4-1%) HP:0012795
27 macular atrophy 58 31 very rare (1%) Very rare (<4-1%) HP:0007401
28 retinal pigment epithelial mottling 58 31 very rare (1%) Very rare (<4-1%) HP:0007814
29 chorioretinal atrophy 58 31 very rare (1%) Very rare (<4-1%) HP:0000533
30 myelitis 58 31 very rare (1%) Very rare (<4-1%) HP:0012486
31 acute demyelinating polyneuropathy 58 31 very rare (1%) Very rare (<4-1%) HP:0007131
32 absent foveal reflex 58 31 very rare (1%) Very rare (<4-1%) HP:0030825
33 congenital intracerebral calcification 58 31 very rare (1%) Very rare (<4-1%) HP:0006906
34 skin rash 58 Very frequent (99-80%)

Symptoms:

12
  • • fever
  • • rash
  • • headaches
  • • joint pain

MGI Mouse Phenotypes related to Zika Fever:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.28 AXL CD209 DDX58 FGA IFNAR1 SH2D3C
Sources

Drugs & Therapeutics for Zika Fever

About this section

Drugs for Zika Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 13)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunologic Factors Phase 2
2
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
3
Aluminum sulfate Approved Phase 1 10043-01-3
4 Pharmaceutical Solutions Phase 1
5 Rho(D) Immune Globulin Phase 1
6 Immunoglobulins, Intravenous Phase 1
7 Immunoglobulin G Phase 1
8 gamma-Globulins Phase 1
9 Antibodies, Blocking Phase 1
10 Immunoglobulins Phase 1
11 Antibodies Phase 1
12 Antibodies, Monoclonal Phase 1
13 Vaccines Phase 1

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections and Treatment Use Open-Label Extension Study Recruiting NCT03037164 Phase 3
2 VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents Completed NCT03110770 Phase 2
3 Safety and Pharmacokinetic Evaluation of Zika Virus Immune Globulin in Healthy Volunteers Completed NCT03624946 Phase 1
4 VRC 319: A Phase I/Ib, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of A Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults Completed NCT02840487 Phase 1
5 VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, in Healthy Adults Completed NCT02996461 Phase 1
6 A Phase 1, First-in-Human, Double-blinded, Randomized, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Healthy Flavivirus-Naïve and Flavivirus-Primed Subjects Completed NCT02963909 Phase 1
7 Phase 1, Double-blinded, Placebo-Controlled Study of the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Flavivirus Naïve Adult Subjects Completed NCT02952833 Phase 1 Saline
8 Phase 1 First in Human, Time Lagged, Parallel-Group, Single Ascending Dose Study of Tyzivumab in Healthy Adult Volunteers Completed NCT03443830 Phase 1 Tyzivumab
9 A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years Completed NCT03343626 Phase 1 Placebo
10 Phase 1, Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial to Evaluate 2 Doses of 3 Sequentially Escalating Cohort of BBV121 in Healthy Adult Dengue Sero-Negative and Dengue Sero-Positive Volunteers Completed NCT04478656 Phase 1
11 Observer Blinded, Randomized Trial to Evaluate Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP Completed NCT04033068 Phase 1
12 A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region Completed NCT03014089 Phase 1
13 Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers Completed NCT02996890 Phase 1
14 Phase I Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults Completed NCT03611946 Phase 1
15 A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika Virus Purified Inactivated Vaccine Plus Alum Adjuvant in Healthy Adults Completed NCT02937233 Phase 1
16 A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess the Safety and Immunogenicity of Two Different Dose Levels of an Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years Completed NCT03425149 Phase 1
17 Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed by EP in Dengue Virus-Naïve Adults Completed NCT02809443 Phase 1
18 Phase 1 Time Lagged, Parallel-Group, Randomized, Placebo-Controlled, Single-Blind, Single Ascending Dose Study of Tyzivumab in ZIKV Infected Patients Recruiting NCT03776695 Phase 1
19 A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Zika Virus (ZIKV) Vaccine ChAdOx1 Zika in Healthy Adult Volunteers Given as a Standalone Vaccine or Co-administered With the Chikungunya Virus (CHIKV) Candidate Vaccine ChAdOx1 Chik Recruiting NCT04015648 Phase 1
20 Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Adult Subjects Who Reside in a Flavivirus Endemic Area Active, not recruiting NCT03008122 Phase 1
21 A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults Active, not recruiting NCT04064905 Phase 1
22 Études Observationnelles Des conséquences néonatales et pédiatriques de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016 Unknown status NCT02810210
23 Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment: Cohort Study in Fiocruz/IFF Unknown status NCT03255369
24 World Mosquito Program - Colombia (WMP-COLOMBIA): The Impact of City-wide Deployment of Wolbachia-infected Mosquitoes on Arboviral Disease Incidence in Medellin and Bello, Colombia Unknown status NCT03631719
25 Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection. Unknown status NCT03161444
26 Risk Evaluation of Fetal Nervous System and Neurodevelopment Disorders in Infants of Women Exposed to Zika Virus Infection During Pregnancy Unknown status NCT02943304
27 Effect of a Posture Adapter Use on Body Alignment in Standing Position on Children Between 12 and 24 Months Old With Zyka Virys Congenital Syndrome Unknown status NCT03227601
28 Études Observationnelles Des conséquences de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016 Unknown status NCT02916732
29 Persistence of Zika Virus in Semen After Acute Infection Completed NCT02733796
30 Prospective Surveillance and Case Definition Study of Zika Virus Disease and Infection in Adolescents and Adults in Latin America in Preparation for an Efficacy Trial of a Zika Virus Whole Virion, Purified Inactivated Vaccine Completed NCT03158233
31 International Prospective Observational Cohort Study of Zika in Infants Completed NCT02856984
32 The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico (Zik01) Completed NCT02831699
33 Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil Completed NCT03106714
34 Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection Completed NCT02979938
35 Rescuing Neurodevelopment in Zika-Exposed Infants in Grenada Completed NCT04697147
36 Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA Completed NCT03776903
37 Sensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection During the First or Second Trimester of Gestation. Completed NCT03679728
38 Efficacy of Aquatic Physiotherapy in Stress Level and Muscle Tone of Children Between 3 and 24 Months With Microcephaly by Zika Virus Congenital Syndrome Completed NCT03330600
39 Study of Zika Virus and Related Arbovirus Infections in Deferred Blood Donors Completed NCT02794181
40 Pilot Study to Detect Zika Virus in Sperm Completed NCT02874456
41 Prospective Cohort Study of HIV and Zika in Infants and Pregnancy Completed NCT03263195
42 Neurovirus Emerging in the Americas Study (NEAS): Neurologic Manifestations of the Arbovirus Dengue, Chikungunya and Zika Infections in Colombia Completed NCT03206541
43 Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose. Recruiting NCT01099852
44 A Cluster-Randomized Trial to EValuate the Efficacy of Wolbachia-InfecTed Aedes Aegypti Mosquitoes in Reducing the Incidence of Arboviral Infection in Brazil Recruiting NCT04514107
45 Children (CH) Cohort for the Evaluation of Developmental and Neurological Abnormalities in Infants Born to Mothers Residing in Areas With Zika Virus Transmission During Pregnancy Recruiting NCT03393286
46 Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia Recruiting NCT03922594
47 The International Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy Recruiting NCT04118738
48 Pregnant Women (PW) Cohort for Evaluation of Risks of Congenital Malformations and Other Adverse Pregnancy Outcomes After Zika Virus Infection (Part of ZIKAlliance) Active, not recruiting NCT03188731
49 Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua Enrolling by invitation NCT04182685
50 Developmental Outcome After In Utero ZIKV Exposure in Children Without Congenital Zika Syndrome Enrolling by invitation NCT04398901

Search NIH Clinical Center for Zika Fever

Cochrane evidence based reviews: zika virus infection

Sources

Genetic Tests for Zika Fever

About this section
Sources

Anatomical Context for Zika Fever

About this section

MalaCards organs/tissues related to Zika Fever:

40
Eye, Placenta, Fetal Brain, Skin, T Cells, Whole Blood, Kidney
Sources

Publications for Zika Fever

About this section

Articles related to Zika Fever:

(show top 50) (show all 1592)
# Title Authors PMID Year
1
Assessment of knowledge, attitudes, and practices towards Zika virus among healthcare workers in St. Kitts. 42
33663410 2021
2
Outbreaks of publications about emerging infectious diseases: the case of SARS-CoV-2 and Zika virus. 42
33706715 2021
3
Dynamics of Transmission of Urban Arbovirus Dengue, Zika and Chikungunya in Southwestern Region of Bahia, Brazil. 42
33681889 2021
4
Hippocampal and Prefrontal Cortical Brain Tissue Levels of Irisin and GDF15 Receptor Subunits in Children. 61
33411243 2021
5
The Zika virus: Lurking behind the COVID-19 pandemic? 61
33217046 2021
6
Vertical transmission of Zika virus and its outcomes: a Bayesian synthesis of prospective studies. 61
33068528 2021
7
Desideratum: a developmentalist view of Zika virus infection. 61
33068527 2021
8
Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection. 61
33689873 2021
9
Reply to letter to the editor: Zika virus infection in pregnant women in Mexico. 61
31072181 2021
10
Parental Stress in Primary Caregivers of Children with Evidence of Congenital Zika Virus Infection in Northeastern Brazil. 61
33245528 2021
11
Intrauterine Zika virus infection: review of the current findings with emphasis in the prenatal and postnatal brain imaging diagnostic methods. 61
33781162 2021
12
Zika virus infection in pregnant travellers and impact on childhood neurodevelopment in the first two years of life: A prospective observational study. 61
33601028 2021
13
The innate immune response in Zika virus infection. 61
32926478 2021
14
Neglected tropical diseases and infectious illnesses: potential targeted peptides employed as hits compounds in drug design. 61
33059502 2021
15
Prolonged Maternal Zika Viremia as a Marker of Adverse Perinatal Outcomes. 61
33496246 2021
16
Defining dysmorphic facial features in congenital Zika syndrome. 61
33215846 2021
17
Exploring for Municipality-Level Socioeconomic Variables Related to Zika Virus Incidence in Colombia. 61
33668584 2021
18
Zika virus testing of asymptomatic patients undergoing assisted reproduction in Curitiba, Brazil. 61
33118718 2021
19
Rearrangement of Actin Cytoskeleton by Zika Virus Infection Facilitates Blood-Testis Barrier Hyperpermeability. 61
33534087 2021
20
Zika virus infection induced apoptosis by modulating the recruitment and activation of pro-apoptotic protein Bax. 61
33536166 2021
21
Rift Valley fever: a threat to pregnant women hiding in plain sight? 61
33597209 2021
22
Transcriptional signatures of Zika virus infection in astrocytes. 61
33405202 2021
23
Evidence of Zika Virus Infection in Pigs and Mosquitoes, Mexico. 61
33496242 2021
24
Two immunogenic recombinant protein vaccine candidates showed disparate protective efficacy against Zika virus infection in rhesus macaques. 61
33451779 2021
25
Surveillance for Vector-borne Diseases Among Active and Reserve Component Service Members, U.S. Armed Forces, 2016-2020. 61
33636087 2021
26
Should obstetricians working in non-endemic countries care about emerging tropical diseases? 61
33359921 2021
27
Current Status and a Perspective of Mosquito-Borne Diseases in the Republic of Korea. 61
33136531 2021
28
New Proteomic Signatures to Distinguish Between Zika and Dengue Infections. 61
33582300 2021
29
[Meanings, risk perceptions, and prevention strategies for pregnant women since the emergence of the Zika virus in Brazil]. 61
33624694 2021
30
Zika virus dynamics: Effects of inoculum dose, the innate immune response and viral interference. 61
33471814 2021
31
Pregnant women infected by the Zika virus: Ultrasound findings and growth patterns of fetuses with and without microcephaly. 61
33404080 2021
32
An Innovative United States-Mexico Community Outreach Initiative for Hispanic and Latino People in the United States: A Collaborative Public Health Network. 61
33478368 2021
33
Investigating into the molecular interactions of flavonoids targeting NS2B-NS3 protease from ZIKA virus through in-silico approaches. 61
31920173 2021
34
Congenital abnormalities associated with Zika virus infection-Dengue as potential co-factor? A systematic review. 61
33395432 2021
35
Enhancement of Zika virus infection by antibodies from West Nile virus seropositive individuals with no history of clinical infection. 61
33421988 2021
36
Emerging Infectious Diseases in Pregnant Women in a Non-Endemic Area: Almost One Out of Four Is at Risk. 61
33435140 2021
37
Clinical and Preclinical Evidence for Adverse Neurodevelopment after Postnatal Zika Virus Infection. 61
33445671 2021
38
Complications and Sequelae in Patients With Congenital Microcephaly Associated With Zika Virus Infection: Two-Year Follow-Up. 61
33406966 2021
39
Common Dysregulation of Innate Immunity Pathways in Human Primary Astrocytes Infected With Chikungunya, Mayaro, Oropouche, and Zika Viruses. 61
33791243 2021
40
Genome-wide identification of Aedes albopictus long noncoding RNAs and their association with dengue and Zika virus infection. 61
33481791 2021
41
Association of Anterior Uveitis With Acute Zika Virus Infection in Adults. 61
33237306 2021
42
Cohort profile: Study on Zika virus infection in Brazil (ZIKABRA study). 61
33400705 2021
43
Correction: Characterization of zika virus infection of human fetal cardiac mesenchymal stromal cells. 61
33481943 2021
44
Zika virus infection in pregnant women in Mexico. 61
30939961 2021
45
Understanding the magnitude of risk associated with Zika virus infection in pregnancy. 61
33007152 2021
46
[Brazilian Protocol for Sexually Transmitted Infections 2020: Zika virus infection]. 61
33729407 2021
47
Early maternal Zika infection predicts severe neonatal neurological damage: results from the prospective Natural History of Zika Virus Infection in Gestation cohort study. 61
32920998 2021
48
Zika virus infection induces endoplasmic reticulum stress and apoptosis in placental trophoblasts. 61
33500388 2021
49
[Intensified epidemiological surveillance of arbovirosis: First case of native dengue fever in Catalonia (Spain), Northern Metropolitan Area of Barcelona, 2018-2019]. 61
33342482 2021
50
Role of Zika virus infection in cases and outbreaks of Guillain-Barré syndrome in Latin America: Pooling the prevalence of studies. 61
33137492 2021
Sources

Variations for Zika Fever

About this section
Sources

Expression for Zika Fever

About this section
Search GEO for disease gene expression data for Zika Fever.
Sources

Pathways for Zika Fever

About this section

Pathways related to Zika Fever according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Herpes simplex virus 1 infection 36
12.26 TLR3 STAT2 IFNAR1 DDX58
2
Measles 36
Show member pathways
 12.06 TLR3 STAT2 IFNAR1 DDX58 CD209
3
Necroptosis 36
Show member pathways
 11.56 TLR3 STAT2 IFNAR1
4
Peginterferon alpha-2a/Peginterferon alpha-2b Pathway (Hepatocyte), Pharmacodynamics 60
Show member pathways
 10.16 STAT2 IFNAR1 DDX58
Sources

GO Terms for Zika Fever

About this section

Cellular components related to Zika Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.02 TYRO3 TLR3 FGA CD209 AXL

Biological processes related to Zika Fever according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.95 TLR3 FGA DDX58 CD209 AXL
2 innate immune response GO:0045087 9.8 TLR3 FGA DDX58 CD209 AXL
3 defense response to virus GO:0051607 9.78 TLR3 STAT2 DDX58
4 viral process GO:0016032 9.72 TYRO3 STAT2 DDX58 CD209 AXL
5 response to virus GO:0009615 9.71 TLR3 IFNAR1 DDX58
6 platelet activation GO:0030168 9.7 TYRO3 FGA AXL
7 viral entry into host cell GO:0046718 9.65 TYRO3 CD209 AXL
8 protein kinase B signaling GO:0043491 9.61 TYRO3 AXL
9 positive regulation of interferon-beta production GO:0032728 9.6 TLR3 DDX58
10 response to exogenous dsRNA GO:0043330 9.59 TLR3 DDX58
11 JAK-STAT cascade GO:0007259 9.58 STAT2 IFNAR1
12 positive regulation of interferon-alpha production GO:0032727 9.58 TLR3 DDX58
13 apoptotic cell clearance GO:0043277 9.57 TYRO3 AXL
14 cellular response to exogenous dsRNA GO:0071360 9.56 TLR3 DDX58
15 cellular response to interferon-alpha GO:0035457 9.51 IFNAR1 AXL
16 natural killer cell differentiation GO:0001779 9.49 TYRO3 AXL
17 vagina development GO:0060068 9.46 TYRO3 AXL
18 secretion by cell GO:0032940 9.43 TYRO3 AXL
19 ovulation cycle GO:0042698 9.37 TYRO3 AXL
20 detection of virus GO:0009597 9.26 TLR3 DDX58
21 negative regulation of lymphocyte activation GO:0051250 9.16 TYRO3 AXL
22 forebrain cell migration GO:0021885 8.96 TYRO3 AXL
23 positive regulation of viral life cycle GO:1903902 8.8 TYRO3 CD209 AXL

Molecular functions related to Zika Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol 3-kinase binding GO:0043548 8.96 TYRO3 AXL
2 virus receptor activity GO:0001618 8.8 TYRO3 CD209 AXL
Sources

Sources for Zika Fever

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....